HSP90AA1 and breast carcinoma: Collectively, we discovered that HSP90 N‐terminal inhibitors disrupt the homodimer formation of oncogenic ATPase MORC2 to induce its autophagic degradation in a HSP90‐independent manner, and consequently, suppress MORC2‐driven breast cancer progression (Figure 7).